Chong Kun Dang to introduce novel ulcerative colitis medication from US-based Salix Pharmaceuticals

Published: 2003-10-22 06:59:00

Updated: 2003-10-22 06:59:00

Chong Kun Dang Pharmaceuticals said it recently signed with the U.S.-based Salix Pharmaceuticals (Dr. Lorin Johnson, a co-founder of Salix), a leading pharmaceutical firm in the sales/marketing of digestive drugs, an exclusive distribution agreement for the marketing of Colazal (balsalazide disod...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK